Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1134

1.

Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease.

Dai Y, Dudek NL, Li Q, Fowler SC, Muma NA.

J Neurosci. 2009 Sep 16;29(37):11550-9. doi: 10.1523/JNEUROSCI.3307-09.2009.

2.

CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model.

Chou SY, Lee YC, Chen HM, Chiang MC, Lai HL, Chang HH, Wu YC, Sun CN, Chien CL, Lin YS, Wang SC, Tung YY, Chang C, Chern Y.

J Neurochem. 2005 Apr;93(2):310-20.

3.

Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.

Yu ZX, Li SH, Evans J, Pillarisetti A, Li H, Li XJ.

J Neurosci. 2003 Mar 15;23(6):2193-202.

4.

Characterization of huntingtin pathologic fragments in human Huntington disease, transgenic mice, and cell models.

Schilling G, Klevytska A, Tebbenkamp AT, Juenemann K, Cooper J, Gonzales V, Slunt H, Poirer M, Ross CA, Borchelt DR.

J Neuropathol Exp Neurol. 2007 Apr;66(4):313-20.

PMID:
17413322
5.

Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease.

Van Raamsdonk JM, Pearson J, Rogers DA, Bissada N, Vogl AW, Hayden MR, Leavitt BR.

Hum Mol Genet. 2005 May 15;14(10):1379-92. Epub 2005 Apr 13.

PMID:
15829505
6.

Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease.

Ebert AD, Barber AE, Heins BM, Svendsen CN.

Exp Neurol. 2010 Jul;224(1):155-62. doi: 10.1016/j.expneurol.2010.03.005. Epub 2010 Mar 19.

PMID:
20227407
7.
8.

The detection and measurement of locomotor deficits in a transgenic mouse model of Huntington's disease are task- and protocol-dependent: influence of non-motor factors on locomotor function.

Pallier PN, Drew CJ, Morton AJ.

Brain Res Bull. 2009 Mar 30;78(6):347-55. doi: 10.1016/j.brainresbull.2008.10.007. Epub 2008 Nov 14.

PMID:
19010400
9.

Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6/1 mice.

Denovan-Wright EM, Attis M, Rodriguez-Lebron E, Mandel RJ.

J Neurosci Res. 2008 Jun;86(8):1748-57. doi: 10.1002/jnr.21636.

10.

Characterization of a rat model of Huntington's disease based on targeted expression of mutant huntingtin in the forebrain using adeno-associated viral vectors.

Gabery S, Sajjad MU, Hult S, Soylu R, Kirik D, Petersén Å.

Eur J Neurosci. 2012 Sep;36(6):2789-800. doi: 10.1111/j.1460-9568.2012.08193.x. Epub 2012 Jun 25.

PMID:
22731249
12.

Protein kinase C beta II mRNA levels decrease in the striatum and cortex of transgenic Huntington's disease mice.

Harris AS, Denovan-Wright EM, Hamilton LC, Robertson HA.

J Psychiatry Neurosci. 2001 Mar;26(2):117-22.

13.
14.

Neuroprotective effects of calmodulin peptide 76-121aa: disruption of calmodulin binding to mutant huntingtin.

Dudek NL, Dai Y, Muma NA.

Brain Pathol. 2010 Jan;20(1):176-89. doi: 10.1111/j.1750-3639.2008.00258.x. Epub 2009 Mar 10.

15.

Age-dependent changes in nitric oxide synthase activity and protein expression in striata of mice transgenic for the Huntington's disease mutation.

Pérez-Severiano F, Escalante B, Vergara P, Ríos C, Segovia J.

Brain Res. 2002 Sep 27;951(1):36-42.

PMID:
12231454
16.

Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice.

Menalled LB, Sison JD, Wu Y, Olivieri M, Li XJ, Li H, Zeitlin S, Chesselet MF.

J Neurosci. 2002 Sep 15;22(18):8266-76.

17.

Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration.

Strand AD, Baquet ZC, Aragaki AK, Holmans P, Yang L, Cleren C, Beal MF, Jones L, Kooperberg C, Olson JM, Jones KR.

J Neurosci. 2007 Oct 24;27(43):11758-68.

18.

Altered serotonin receptor expression is associated with depression-related behavior in the R6/1 transgenic mouse model of Huntington's disease.

Pang TY, Du X, Zajac MS, Howard ML, Hannan AJ.

Hum Mol Genet. 2009 Feb 15;18(4):753-66. doi: 10.1093/hmg/ddn385. Epub 2008 Nov 13.

PMID:
19008301
19.

Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation.

Zourlidou A, Gidalevitz T, Kristiansen M, Landles C, Woodman B, Wells DJ, Latchman DS, de Belleroche J, Tabrizi SJ, Morimoto RI, Bates GP.

Hum Mol Genet. 2007 May 1;16(9):1078-90. Epub 2007 Mar 14.

PMID:
17360721
20.

Blocking acid-sensing ion channel 1 alleviates Huntington's disease pathology via an ubiquitin-proteasome system-dependent mechanism.

Wong HK, Bauer PO, Kurosawa M, Goswami A, Washizu C, Machida Y, Tosaki A, Yamada M, Knöpfel T, Nakamura T, Nukina N.

Hum Mol Genet. 2008 Oct 15;17(20):3223-35. doi: 10.1093/hmg/ddn218. Epub 2008 Jul 24.

PMID:
18658163

Supplemental Content

Support Center